膵臓がんの世界市場-2023年～2030年

市場概要

世界の膵臓がん市場は2022年に25億米ドルに達し、2030年には57億米ドルに達することで有利な成長を示すと予測されています。世界の膵臓がん市場は予測期間（2023-2030年）にCAGR 11.1%を示すと予測されています。

膵臓には悪性腫瘍と非がん性腫瘍の両方が発生する可能性があります。膵臓がんの最も一般的な形態である膵管腺がんは、膵臓から消化酵素を除去する管を裏打ちする細胞に発生します。膵臓がんが最も治療可能な初期段階で発見されることはまれです。これは、他の臓器に転移するまで症状が現れないことが多いためです。

市場力学

活発な主要プレーヤーが予測期間中の世界膵臓がん市場の成長を後押しする

2023年5月、「デジタルツイン」とコーザルAIの作成と利用のパイオニアであるアイティアは、セルヴィエと提携し、膵臓がんとの闘いを支援する新しいジェミニ・デジタルツインを構築しました。この提携は、2022年に初めて発表された多発性骨髄腫の提携を拡大するものです。

契約によると、アイティアとセルヴィエ社は、セルヴィエ社の前臨床試験法、治療薬創製プラットフォーム、専門知識とアイティア社の膵臓がんデジタルツインを用いて、膵臓がんにおける新規創薬ターゲットと創薬候補を同定、検証し、開発を試みるためのトランスレーショナルな問題に焦点を当てるために協力します。いくつかの新規創薬標的は、独占的オプションのもと、セルヴィエ社によって研究開発され、商品化される予定です。

研究開発の進展が世界の膵臓がん市場の成長機会をもたらす

2022年9月、「STarT Pancreas」はServierとOncodesign Precision Medicine（OPM）の間で締結された、膵管腺がんの新たな治療標的の発見と検証を目的とした共同研究契約の名称です。

セルヴィエとオンコデザイン・プレシジョン・メディシン（OPM）の3年間の契約には、OncoSNIPE臨床試験のデータを用いてAI分析プラットフォームを共同で構築し、そのプラットフォームを用いてターゲットを同定し、そして事前に選択されたターゲットを実験的に検証するという2つのステップが含まれています。

COVID-19影響分析

COVID-19の大流行は、膵臓がん市場に大きな影響を与えました。膵臓がんやその他のがんの臨床試験もパンデミックの影響を受けています。参加者と医療関係者の安全のため、いくつかの研究は一時的に中止されたり変更されたりしました。このことは、新規治療法の創出や、膵臓がん患者の臨床試験へのアクセスに影響を及ぼしています。

ロシア・ウクライナ紛争分析

ロシア・ウクライナ紛争が膵臓がん市場に与えた影響は複雑かつ多面的です。影響を受けた地域では、暴力がヘルスケアシステムとサービスに負担をかけました。本来であればがん治療に充てられるはずの資金を、紛争による差し迫った需要に対処するために振り向ける必要が生じる可能性があります。このことは、医療サービスの水準や利用しやすさ、特に膵臓がん患者の診断、治療、支持療法へのアクセスに影響を及ぼします。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

• 影響要因
  • 促進要因
    • 膵臓がんの有病率の上昇
  • 抑制要因
    • 治療薬に伴う副作用
  • 機会
    • 技術の進歩
  • 影響分析

第5章 産業分析

• ポーターの5フォース分析
• サプライチェーン分析
• アンメットニーズ
• 規制分析

第6章 COVID-19分析

第7章 ロシア・ウクライナ戦争分析

第8章 人工知能分析

第9章 治療タイプ別

• 標的療法
• 化学療法
• 外科治療
• その他の治療

第10章 エンドユーザー別

• 病院
• 専門クリニック
• 在宅医療
• その他

第11章 地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • イタリア
  • スペイン
  • その他欧州
• 南米
  • ブラジル
  • アルゼンチン
  • その他南米
• アジア太平洋
  • 中国
  • インド
  • 日本
  • オーストラリア
  • その他アジア太平洋地域
• 中東・アフリカ

第12章 競合情勢

• 競合シナリオ
• 製品ベンチマーク
• 企業シェア分析
• 主な発展と戦略

第13章 企業プロファイル

• Myriad Genetics Inc.
  • 会社概要
  • 製品ポートフォリオと説明
  • 財務概要
  • 主な発展
• Pfizer Inc.
• Novartis AG
• Bristol-Myers Squibb Company
• AstraZeneca PLC
• Amgen Inc.
• Viatris Inc.
• Boston Scientific Corporation
• Clovis Oncology
• GlaxoSmithKline

第14章 付録

Market Overview

The global pancreatic cancer market reached US$ 2.5 billion in 2022 and is projected to witness lucrative growth by reaching up to US$ 5.7 billion by 2030. The global Pancreatic Cancer market is expected to exhibit a CAGR of 11.1% during the forecast period (2023-2030).

The pancreas can develop both malignant and non-cancerous tumors, among other growths. Pancreatic ductal adenocarcinoma, the most prevalent form of pancreatic cancer, develops in the cells lining the ducts that remove digestive enzymes from the pancreas. Rarely is pancreatic cancer found in its earliest stages, when it is most treatable. This is due to the fact that symptoms frequently don't appear until the disease has spread to other organs.

Market Dynamics

Active Major Players are Boosting the Global Pancreatic Cancer Market Growth During The Forecast Period

In May 2023, Aitia, a pioneer in the creation and use of "Digital Twins" and Causal AI, joined up with Servier to build new Gemini Digital Twins to aid in the fight against pancreatic cancer. This partnership expands on one that was first announced in 2022 for multiple myeloma.

According to the agreement, Aitia and Servier will collaborate to use Servier's pre-clinical assays, therapeutic creation platforms, and expertise along with Aitia's pancreatic cancer digital twins to focus on translational questions to identify, validate, and attempt to develop novel drug targets and drug candidates in pancreatic cancer. Several novel drug targets will be researched for, developed for, and commercialized by Servier under an exclusive option.

Increasing Research and Development Provide Global Pancreatic Cancer Market Growth Opportunities

In September 2022, 'STarT Pancreas' is the name of a cooperative research agreement between Servier and Oncodesign Precision Medicine (OPM) to find and validate new treatment targets for pancreatic ductal adenocarcinoma.

Two steps are included in the three-year agreement between Servier and Oncodesign Precision Medicine (OPM): using data from the OncoSNIPE clinical trial to jointly build an AI analytical platform, identify targets using that platform, and then experimentally validate the pre-selected targets.

COVID-19 Impact Analysis

The COVID-19 pandemic has had a significant impact on the pancreatic cancer market. Clinical trials for pancreatic cancer and other cancers have also been impacted by the pandemic. For the sake of the security of participants and medical personnel, several studies were momentarily stopped or altered. This has impacted the creation of novel treatments and the accessibility of clinical trial alternatives for people with pancreatic cancer.

Russia-Ukraine Conflict Analysis

The impact of the Russia-Ukraine war on the pancreatic cancer market is complex and multifaceted. In the impacted areas, the violence put a strain on the healthcare system and services. It could be necessary to redirect funds that would otherwise be allotted to cancer treatment in order to take care of the conflict's immediate demands. This have an effect on the standard of care and accessibility of healthcare services, particularly pancreatic cancer patients' access to diagnosis, treatment, and supportive care.

Segment Analysis

The global pancreatic cancer market is segmented based on type, distribution channel, end-user, and region.

Chemotherapy Segment is Expected to Hold A Dominant Position in the Market Over the Forecast Period

The chemotherapy segment accounted for the highest market stake accounting for approximately 37.6% of the pancreatic cancer market in 2022. Chemotherapy is typically most successful when two or more medications are administered concurrently (particularly as adjuvant or neoadjuvant therapy). A single medication (often gemcitabine, 5-FU, or capecitabine) may be administered for patients who are not healthy enough for combination therapies.

Gemcitabine, 5-fluorouracil (5-FU), Oxaliplatin, Albumin-bound Paclitaxel (Abraxane), Capecitabine (an oral 5-FU medicine), Cisplatin, and Irinotecan are the most popular medications used for both adjuvant and neoadjuvant chemotherapy.

Geographical Analysis

Increasing Collaborations And Partnerships Among The Key Players, And Advancement In Pancreatic Cancer are Factors Driving The European Region

Europe is expected to account for 32.7% of the pancreatic cancer market. For instance, in March 2023, in order to create tailored micro-interfering RNAs (miRNA) for the treatment of cancer, with an initial focus on pancreatic cancer, SiSaf Ltd, a business that specializes in RNA delivery and therapies, will work with the University of Leipzig in Germany.

The cooperation will bring together the expertise of the University of Leipzig in miRNA targeting and cancer therapy strategies with SiSaf's work in RNA delivery utilizing its Bio-Courier silicon-stabilized hybrid lipid nanoparticles (sshLNPs).

Competitive Landscape

The major global players in the market include: Myriad Genetics Inc., Pfizer Inc., Novartis AG, Bristol-Myers Squibb Company, AstraZeneca PLC, Amgen Inc., Viatris Inc., Boston Scientific Corporation, FUJIFILM Holdings Corporation, and Canon Inc. among others.

Why Purchase the Report?

• To visualize the global pancreatic cancer market segmentation based on the type, distribution channel, end-user, and region, as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of pancreatic cancer market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global pancreatic cancer market report would provide approximately 61 tables, 57 figures, and 195 Pages.

Target Audience 2023

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

• 3.1. Snippet By Treatment Type
• 3.2. Snippet by End-user
• 3.3. Snippet by Region

4. Dynamics

• 4.1. Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. Rising prevalence of pancreatic cancer
  • 4.1.2. Restraints
    • 4.1.2.1. Side effects associated with therapeutics
  • 4.1.3. Opportunity
    • 4.1.3.1. Technological advancements
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's 5 Forces Analysis
• 5.2. Supply Chain Analysis
• 5.3. Unmet Needs
• 5.4. Regulatory Analysis

6. COVID-19 Analysis

• 6.1. Analysis of COVID-19
  • 6.1.1. Scenario Before COVID-19
  • 6.1.2. Scenario During COVID-19
  • 6.1.3. Scenario Post COVID-19
• 6.2. Pricing Dynamics Amid COVID-19
• 6.3. Demand-Supply Spectrum
• 6.4. Government Initiatives Related to the Market During the Pandemic
• 6.5. Manufacturers' Strategic Initiatives
• 6.6. Conclusion

7. Russia-Ukraine War Analysis

8. Artificial Intelligence Analysis

9. By Treatment Type

• 9.1. Introduction
  • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
  • 9.1.2. Market Attractiveness Index, By Treatment Type
  • 9.1.3. Targeted Therapies*
  • 9.1.4. Introduction
  • 9.1.5. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.1.6. Chemotherapy
  • 9.1.7. Surgery
  • 9.1.8. Other Treatments

10. By End-user

• 10.1. Introduction
  • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
  • 10.1.2. Market Attractiveness Index, By End-user
• 10.2. Hospitals*
  • 10.2.1. Introduction
  • 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 10.3. Specialty Clinics
• 10.4. Home care
• 10.5. Others

11. By Region

• 11.1. Introduction
  • 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 11.1.2. Market Attractiveness Index, By Region
• 11.2. North America
  • 11.2.1. Introduction
  • 11.2.2. Key Region-Specific Dynamics
  • 11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
  • 11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
  • 11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 11.2.5.1. U.S.
    • 11.2.5.2. Canada
    • 11.2.5.3. Mexico
• 11.3. Europe
  • 11.3.1. Introduction
  • 11.3.2. Key Region-Specific Dynamics
  • 11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
  • 11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
  • 11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 11.3.5.1. Germany
    • 11.3.5.2. U.K.
    • 11.3.5.3. France
    • 11.3.5.4. Italy
    • 11.3.5.5. Spain
    • 11.3.5.6. Rest of Europe
• 11.4. South America
  • 11.4.1. Introduction
  • 11.4.2. Key Region-Specific Dynamics
  • 11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
  • 11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
  • 11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 11.4.5.1. Brazil
    • 11.4.5.2. Argentina
    • 11.4.5.3. Rest of South America
• 11.5. Asia-Pacific
  • 11.5.1. Introduction
  • 11.5.2. Key Region-Specific Dynamics
  • 11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
  • 11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
  • 11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 11.5.5.1. China
    • 11.5.5.2. India
    • 11.5.5.3. Japan
    • 11.5.5.4. Australia
    • 11.5.5.5. Rest of Asia-Pacific
• 11.6. Middle East and Africa
  • 11.6.1. Introduction
  • 11.6.2. Key Region-Specific Dynamics
  • 11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
  • 11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user

12. Competitive Landscape

• 12.1. Competitive Scenario
• 12.2. Product Benchmarking
• 12.3. Company Share Analysis
• 12.4. Key Developments and Strategies

13. Company Profiles

• 13.1. Myriad Genetics Inc.*
  • 13.1.1. Company Overview
  • 13.1.2. Product Portfolio and Description
  • 13.1.3. Financial Overview
  • 13.1.4. Key Developments
• 13.2. Pfizer Inc.
• 13.3. Novartis AG
• 13.4. Bristol-Myers Squibb Company
• 13.5. AstraZeneca PLC
• 13.6. Amgen Inc.
• 13.7. Viatris Inc.
• 13.8. Boston Scientific Corporation
• 13.9. Clovis Oncology
• 13.10. GlaxoSmithKline

LIST NOT EXHAUSTIVE

14. Appendix

• 14.1. About Us and Services
• 14.2. Contact Us